Hemostemix Inc. (CVE:HEM – Get Free Report) shares traded up 7.3% on Wednesday . The company traded as high as C$0.30 and last traded at C$0.30. 107,500 shares were traded during trading, a decline of 84% from the average session volume of 657,849 shares. The stock had previously closed at C$0.28.
Hemostemix Stock Performance
The stock has a 50 day moving average of C$0.12 and a 200-day moving average of C$0.09. The company has a market cap of C$32.67 million, a PE ratio of -18.75 and a beta of 0.20.
About Hemostemix
Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia.
Recommended Stories
- Five stocks we like better than Hemostemix
- What is an Earnings Surprise?
- Why Energy Transfer Stock Could Soar to New Highs in 2025
- Stock Splits, Do They Really Impact Investors?
- 3 Buy-and-Hold Stocks for Long-Term Growth
- What Are Dividend Challengers?
- Despite Short-Term Risks Freeport McMoran Worth a Look
Receive News & Ratings for Hemostemix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemostemix and related companies with MarketBeat.com's FREE daily email newsletter.
